X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (49) 49
index medicus (49) 49
cell line, tumor (29) 29
oncology (28) 28
cancer (22) 22
mutation (22) 22
article (21) 21
proto-oncogene proteins b-raf - genetics (21) 21
animals (20) 20
melanoma (19) 19
tumors (18) 18
protein kinase inhibitors - pharmacology (17) 17
braf (16) 16
female (15) 15
mice (15) 15
kinases (14) 14
signal transduction (14) 14
mutations (13) 13
proteins (13) 13
antineoplastic agents - pharmacology (12) 12
cell biology (12) 12
phosphorylation (12) 12
biology (11) 11
activation (10) 10
map kinase signaling system - drug effects (10) 10
metastasis (10) 10
multidisciplinary sciences (10) 10
genetic aspects (9) 9
neoplasms - genetics (9) 9
pathway (9) 9
proto-oncogene proteins b-raf - metabolism (9) 9
research (9) 9
research article (9) 9
b-raf (8) 8
benzamides - pharmacology (8) 8
cell lines (8) 8
diphenylamine - analogs & derivatives (8) 8
diphenylamine - pharmacology (8) 8
expression (8) 8
extracellular signal-regulated map kinases - metabolism (8) 8
genes (8) 8
inhibition (8) 8
male (8) 8
melanoma - genetics (8) 8
mitogen-activated protein kinase kinases - antagonists & inhibitors (8) 8
ras proteins - genetics (8) 8
xenograft model antitumor assays (8) 8
acquired-resistance (7) 7
cancer therapies (7) 7
gene mutations (7) 7
genes, ras (7) 7
map kinase (7) 7
mek inhibitors (7) 7
mitogen-activated protein kinase kinases - metabolism (7) 7
neoplasms - drug therapy (7) 7
neoplasms - enzymology (7) 7
phosphorylation - drug effects (7) 7
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
care and treatment (6) 6
cell lung-cancer (6) 6
cell proliferation (6) 6
cell proliferation - drug effects (6) 6
drug resistance (6) 6
drug resistance, neoplasm - genetics (6) 6
extracellular signal-regulated kinase (6) 6
gefitinib (6) 6
gene (6) 6
gene expression (6) 6
health aspects (6) 6
in-vivo (6) 6
inhibitors (6) 6
lung neoplasms - genetics (6) 6
lung-cancer (6) 6
medical research (6) 6
melanoma - drug therapy (6) 6
neoplasms (6) 6
proto-oncogene proteins b-raf - antagonists & inhibitors (6) 6
resistance (6) 6
signal transduction - drug effects (6) 6
vemurafenib (6) 6
adult (5) 5
benzimidazoles - pharmacology (5) 5
biochemistry & molecular biology (5) 5
breast-cancer (5) 5
clinical trials as topic (5) 5
combination therapy (5) 5
feedback (5) 5
feedback inhibition (5) 5
gene expression profiling (5) 5
gene expression regulation, neoplastic - drug effects (5) 5
genomics (5) 5
growth (5) 5
indoles - pharmacology (5) 5
kinase (5) 5
map kinase signaling system (5) 5
mathematical models (5) 5
mice, nude (5) 5
models, biological (5) 5
pathways (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2010, Volume 107, Issue 33, pp. 14903 - 14908
Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK)... 
Tumor cell line | Phosphorylation | Cell growth | Negative feedback | Genes | Cell lines | Melanoma | Genetic mutation | Tumors | Cancer | LUNG-CANCER | APOPTOSIS | KINASE KINASE-1/2 INHIBITOR | ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | IN-VIVO | B-RAF | MUTATIONS | MEK INHIBITORS | ADVANCED CANCERS | Diphenylamine - pharmacology | Oligonucleotide Array Sequence Analysis | Apoptosis - drug effects | Humans | Gene Expression Profiling | Extracellular Signal-Regulated MAP Kinases - metabolism | Diphenylamine - analogs & derivatives | Mitogen-Activated Protein Kinase Kinases - metabolism | Indoles - pharmacology | Benzamides - pharmacology | G1 Phase - genetics | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Proto-Oncogene Proteins B-raf - metabolism | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Blotting, Western | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Mutation | Amino Acid Substitution | Cell proliferation | Development and progression | Cellular signal transduction | Genetic aspects | Pharmacology | Research | Drug therapy | Proteins | Signal transduction | Kinases | Gene expression | Cells | Index Medicus | Biological Sciences
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 03/2009, Volume 106, Issue 11, pp. 4519 - 4524
Tumors with mutant BRAF and those with receptor tyrosine kinase (RTK) activation have similar levels of phosphorylated ERK, but only the former depend on ERK... 
Braf mutation | Mitogen-activated protein kinase | Extracellular signal-regulated kinase kinase inhibition | Dual specificity phosphatase | dual specificity phosphatase | mitogen-activated protein kinase, extracellular signal-regulated kinase kinase inhibition | Biological Sciences | BRAF mutation
Journal Article
Journal Article
Nature Cell Biology, ISSN 1465-7392, 01/2015, Volume 17, Issue 1, pp. 81 - 94
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 6, p. e0217399
The clinical significance of BRAF alterations in well-differentiated (WD) metastatic pancreatic neuroendocrine tumor (panNET) is unknown, but BRAF-mutated... 
Medicine, Experimental | Medical research | Research | Gene mutations | Model testing | Genomics | MEK inhibitors | Melanoma | Extracellular signal-regulated kinase | Raf protein | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Mutants | 1-Phosphatidylinositol 3-kinase | Metastases | Medicine | Alterations | Inhibitors | Mutation | Inhibition | Pancreas | Tumors | Neuroendocrine tumors
Journal Article
Cancers, ISSN 2072-6694, 08/2019, Volume 11, Issue 9, p. 1262
BRAF mutations have been identified as targetable, oncogenic mutations in many cancers. Given the paucity of treatments for primary brain tumors and the poor... 
trametinib | BRAF V600E | MEK | glioblastoma | astrocytoma | vemurafenib | glioma | BRAF | dabrafenib | encorafenib
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 05/2015, Volume 62, Issue 5, pp. 798 - 806
Journal Article
Nature cell biology, ISSN 1465-7392, 04/2019, Volume 21, Issue 4, pp. 534 - 534
In the version of this Article originally published the same blot was inadvertently presented as both p-Rb and Cyclin A in Fig. 2a. This blot corresponds to... 
Cells | Tumors | Signal transduction | MAP kinase | Tumorigenesis | Plasmids | Cyclin A | Guanosinetriphosphatase
Journal Article
Cancer Cell, ISSN 1535-6108, 11/2012, Volume 22, Issue 5, pp. 668 - 682
Journal Article
Acta neuropathologica communications, ISSN 2051-5960, 08/2019, Volume 7, Issue 1, pp. 139 - 11
The presence of Alternative lengthening of telomeres (ALT) and/or ATRX loss, as well as the role of other telomere abnormalities, have not been formally... 
GLIOMAS | SUZ12 | ATRX | LENGTH | PHENOTYPE | SUBSET | NEUROSCIENCES | MPNST | Glioma | DIFFUSE | NF1 | MUTATIONS | Alternative lengthening of telomeres | EXPRESSION | NERVE SHEATH TUMORS | Telomeres | Gliomas | Telomerase | Tumors
Journal Article